

Characterization of disease course and remission in early seropositive rheumatoid arthritis

1   **Running Title:**

2   Characterization of disease course and remission in early seropositive rheumatoid arthritis

3   **Title:**

4   Characterization of disease course and remission in early seropositive rheumatoid arthritis: Results

5   from the TACERA longitudinal cohort study

6   **Authors:**

7   RA-MAP Consortium,

8   United Kingdom

9   **Correspondence to:**

10   Dr Brian Tom (PhD),

11   MRC Biostatistics Unit,

12   University of Cambridge,

13   United Kingdom

14   e-mail: [brian.tom@mrc-bsu.cam.ac.uk](mailto:brian.tom@mrc-bsu.cam.ac.uk)

15   **Word count:** Main – 3521

## Characterization of disease course and remission in early seropositive rheumatoid arthritis

### 16 ABSTRACT

17 **Background:** To characterize disease course and remission in a longitudinal observational study of  
18 newly diagnosed, initially treatment naïve patients with seropositive rheumatoid arthritis (RA).

19 **Methods:** Patients with early untreated seropositive RA were recruited from 28 UK centres. Multiple  
20 clinical and laboratory measures were collected every 3 months for up to 18 months. Disease  
21 activity was measured using DAS28-CRP and SDAI. Logistic regression models examined clinical  
22 predictors of 6-month remission and latent class mixed models characterized disease course.

23 **Results:** We enrolled 275 patients of whom 267 met full eligibility and provided baseline data.  
24 According to SDAI definition, 24.3% attained 6-month remission. Lower baseline HAQ and SDAI  
25 predicted 6-month remission ( $p=0.002$  and 0.021). Alcohol intake and baseline prescribing of  
26 methotrexate with a second DMARD (versus monotherapy without glucocorticoids) were also  
27 predictive. Three distinct SDAI trajectory subpopulations emerged; corresponding to an Inadequate  
28 Responder group (6.5%), and Higher and Lower Baseline Activity Responder groups (22.4% and  
29 71.1%). Baseline HAQ and SF-36 MCS only distinguished these groups. Additionally a number of  
30 baseline clinical predictors correlated with disease activity severity within subpopulations. Beneficial  
31 effects of alcohol intake were found across subpopulations.

32 **Conclusions:** Three distinct disease trajectory subpopulations were identified. Differential effects of  
33 functional and mental well-being, alcohol consumption and baseline RA medication prescribing on  
34 disease activity severity were found across subpopulations. Heterogeneity across trajectories cannot  
35 be fully explained by baseline clinical predictors. Biological markers collected early in disease course  
36 (within 6 months) may help patient management and to better target existing and novel therapies.

37 **Keywords:** Disease activity, latent class mixed models, remission, rheumatoid arthritis, SDAI  
38 trajectories

39 **Word count:** Abstract – 248; Main – 3483

## Characterization of disease course and remission in early seropositive rheumatoid arthritis

40

### 41 BACKGROUND

42 Early diagnosis and prompt, tight control of disease activity have been proven to alter long-term  
43 course of rheumatoid arthritis (RA) and limit structural damage and long-term disability.(1) In spite  
44 of a range of synthetic and biological disease modifying anti-rheumatic drugs, clinical remission is  
45 achieved and sustained in a minority and drug-free remission remains rare.(2) This may be due to  
46 many factors. For example, there are no validated instruments for reliably predicting prognosis. Nor  
47 is it possible to confidently predict which patients will respond more favourably to one particular  
48 drug or drug combination over another. Furthermore, our understanding of low disease activity  
49 states is limited.(3,4) The ability to employ the most appropriate ‘treat-to-target strategy’ to the  
50 right set of early RA patients would be a major advance. Recent evidence suggests that, for early RA  
51 patients following a treat-to-target strategy, distinct trajectories of disease activity over the first year  
52 exist.(5) Moreover, evidence from long-term observational cohorts has suggested that distinct  
53 trajectories linked to prognosis exist; which may point to distinct immunopathogenic subsets.(6)  
54 Even ACPA positive disease is heterogeneous in outcomes (e.g. radiological progression), further  
55 adding to arguments favouring a stratified medicine approach.(7,8)

56 To facilitate the goals of the RA MRC/ABPI (RA-MAP) Consortium,(9) a cohort of newly diagnosed  
57 seropositive RA patients – the ‘Towards A CurE for RA’ (TACERA) cohort – was established and  
58 followed frequently and deeply phenotyped. The aim of the current study was two-fold. Firstly, we  
59 aimed to determine if baseline clinical factors and RA-prescribed medications are associated with 6-  
60 month remission in seropositive early RA. However, an analysis at a single time point neither  
61 reflects longitudinal disease activity patterns nor what factors predict, for example, sustained  
62 remission, fluctuating disease activity course, or gradual versus rapid response. Therefore secondly,  
63 we aimed to (i) determine whether different types of disease activity trajectory sub-populations  
64 exist within this inception cohort; (ii) identify factors associated with longitudinal disease activity;

## Characterization of disease course and remission in early seropositive rheumatoid arthritis

65 and (iii) determine whether differences in trajectory types (if they exist) associate with disease  
66 outcomes, baseline RA-prescribed medication, smoking status and alcohol consumption.  
67 Identification of factors associated with disease activity and characterization of subgroups may  
68 improve patients' treatment and management and identify the most suitable patients for  
69 recruitment into trials.

70

## 71 METHODS

### 72 Patients

73 We recruited newly diagnosed patients ≥18 years of age with symptom duration <12 months who  
74 fulfilled either the 1987 American College of Rheumatology (ACR) or 2010 European League Against  
75 Rheumatism (EULAR)/ACR classification criteria for RA.(10,11) Patients were required to be ACPA  
76 and/or RF positive and naïve to DMARDs or glucocorticoid therapy. Additionally, for patients  
77 recruited there needed to be a clear intention by the supervising rheumatologist to commence  
78 therapy with DMARDs. Patients were excluded if they had significant comorbidities or if pregnant or  
79 wishing to conceive. Participation in trials impacting on patient's treatment, immune status or  
80 disease activity during the study period was not permitted. Ethical approval was authorised by the  
81 National Research Ethics Service London Central Committee (Reference number: 12/LO/0469).  
82 Informed, written consent was obtained.

### 83 Study Design

84 Subjects were recruited from 28 UK centres. Study sample size was determined as described in  
85 supplementary material. Following enrolment, subjects received treatment using conventional  
86 synthetic DMARDs (csDMARDs), with therapy adjustments made at the supervising rheumatologist's  
87 discretion according to the National Institute for Health and Clinical Excellence (NICE) guidelines for  
88 RA management in adults.(12) Patients were followed for a period of 18, 12 or 6 months, dependent

## Characterization of disease course and remission in early seropositive rheumatoid arthritis

89 on time of enrolment (i.e. pre 01/07/14, 01/07/14-31/12/14, post 31/12/14), and seen quarterly for  
90 scheduled assessments. Clinical, laboratory, lifestyle, medication, patient-reported outcome  
91 measures (PROMs), extra-articular RA features, adverse events and biological samples were  
92 collected at visits. Additionally, radiographs of the hands and feet were performed at baseline and  
93 12 months or baseline and 6 months for subjects entering within the third enrolment period.

### 94 *Biological Treatment*

95 Subjects with inadequate clinical responses to csDMARDs and persistent high disease activity (DAS28  
96 > 5.1) at 6 months could receive biological DMARDs (bDMARDs), according to NICE guidelines.

### 97 *Outcome measures*

98 The co-primary outcomes were disease remission at 6 months and repeated disease activity over  
99 time. Disease activity was measured using both composite DAS28-CRP (4-component) and SDAI  
100 scores.(13–16) Disease remission was defined using both DAS28-CRP remission criterion (DAS28-CRP  
101 < 2.6) and the more stringent SDAI criterion (SDAI ≤ 3.3).

102 Secondary outcome measures included the ACR/EULAR Boolean definition of remission(17), DAS28-  
103 ESR, annualized rate of radiographic damage progression as measured by modified Larsen's  
104 score(18–20), functional disability as measured by the Health Assessment Questionnaire (HAQ)(21),  
105 and quality of life using both the Medical Outcomes Study Short Form 36 Health Survey (SF-36) and  
106 EuroQoL five dimensions questionnaire (EQ-5D).(22–24)

### 107 *Statistical methods*

108 Baseline and 6-month information were summarised using the mean, with accompanying standard  
109 deviation (SD) for continuous variables, whilst binary or categorical variables were summarised using  
110 frequency and percentage.

## Characterization of disease course and remission in early seropositive rheumatoid arthritis

111 Stepwise logistic regression models were employed to identify baseline predictors of 6-month  
112 clinical remission. Considered predictors comprised age, sex, ethnicity, body mass index, symptom  
113 duration, smoking status, baseline disease activity, HAQ, SF-36 Mental Component Score, alcohol  
114 consumption, serology (rheumatoid factor (RF) and ACPA), smoking, erosions and prescribing of (or  
115 baseline intention to prescribe) RA medications.

116 Latent class mixed models (LCMM) were used to cluster disease activity trajectories that may  
117 identify clinically important sub-populations and characterize disease activity longitudinally. Within  
118 each latent class, fixed and random patient-level intercepts and piecewise linear time effects (at 5  
119 months) were considered for the linear mixed model part along with potential predictors. No  
120 covariates were included in the class membership model part. Latent class mixed models are  
121 likelihood-based methods, which are valid using only observed data, under a missing-at-random  
122 assumption. Associations of latent trajectory classes with outcomes, baseline RA medication  
123 prescribing, alcohol and smoking status were assessed either using analysis of variance or Fisher's  
124 exact test. For the purpose of these association tests, patients were allocated to particular latent  
125 trajectory class where their calculated assignment posterior probability was highest.

126 Statistical analyses were performed using R statistical software.(25) Two patients, not prescribed RA  
127 medications within the first three months, were excluded from the regression analyses.

128

## 129 RESULTS

### 130 *Patient Characteristics*

131 Two hundred and seventy five patients were recruited of whom 270 fulfilled all eligibility criteria.  
132 Two eligible patients withdrew at baseline without providing any clinical information. A further  
133 patient who withdrew at baseline had some clinical information but insufficient to calculate disease  
134 activity scores. Table 1 summarises the baseline characteristics of the remaining 267 patients.

## Characterization of disease course and remission in early seropositive rheumatoid arthritis

135 Briefly, the mean age at entry was 53.1 (SD of 15.2); 72% were female, 72.7% white, 31.8% healthy  
136 weight and the mean Charlson's comorbidity index (CCI),<sup>(26)</sup> modified to exclude rheumatic disease  
137 as this applied to all subjects, was 0.44 (SD of 0.84), conforming to the intention of not recruiting  
138 patients with significant comorbidities.

139 Of the 267 patients, 130 (48.7%), 67 (25.1%) and 70 (26.2%) were enrolled in the first, second and  
140 third recruitment periods respectively. No statistically significant differences were found across  
141 these three groups with respect to disease-related variables, prescribed medication, and PROMs at  
142 baseline. However there were statistically significant differences found in the age, ethnicity, alcohol  
143 consumption and CCI distributions, with the third group being the oldest on average (51.5 vs 53 vs  
144 56 years old), having the highest proportion of whites (71.5% vs 62.7% vs 84.3%), lowest proportion  
145 not consuming alcohol at entry (32.3% vs 44.8% vs 20%) and lowest levels of comorbidities (CCIs of  
146 0.52 v 0.49 v 0.26).

147 Overall, patients had moderate to severe disease at baseline as measured by both DAS28-CRP and  
148 SDAI. After baseline assessment, MTX was prescribed to 75.7% of patients; 58.4% were prescribed  
149 non-methotrexate major DMARDs (51.7% hydroxychloroquine alone, 5.7% sulfasalazine alone and  
150 1.1% both hydroxychloroquine and sulfasalazine); 6.4% received oral glucocorticoids (average  
151 prednisolone dose of 11.1 mg/day, range 4mg/day to 30mg/day) and 47.2% parenteral  
152 glucocorticoids (i.e. intra-articular, intravenous or intramuscular glucocorticoid administration).  
153 Overall, 33% were prescribed only one class/type of medication, whilst 66.3% were prescribed  
154 combination therapy (including with glucocorticoids) at baseline. Based on medication patterns at  
155 baseline, 26.6%, 19.9% and 52.8% were prescribed single RA therapy excluding glucocorticoids, dual  
156 therapy (i.e. MTX with another DMARD excluding glucocorticoids), and therapies that included  
157 glucocorticoid usage respectively. Initial pattern of therapy did not appear to associate with either  
158 baseline X-ray scores or CCI ( $p=0.56$  and 0.23 respectively) but, as expected, was associated with  
159 disease activity measured using both SDAI and DAS28-CRP ( $p=0.01$  and 0.004 respectively). Two

## Characterization of disease course and remission in early seropositive rheumatoid arthritis

160 subjects did not receive any RA medication by the time of their first follow-up assessment and were  
161 excluded from analyses.

### 162 *Disease activity, response and remission at 6 months*

163 Two hundred and forty five patients (of the 267) were followed up to or beyond their 6-month  
164 assessment visit, with 75, 2, 60, 3 and 105 having their last assessment visit at 6, 9, 12, 15 and 18  
165 months respectively. Of those recruited in the first, second and third periods, 80.8% (105), 83.6%  
166 (56) and 92.9% (65) reached their target follow-up assessment visits of 18 months, 12 months and 6  
167 months respectively. Of the 245 followed up to or beyond 6 months, 239 attended their 6-month  
168 assessment visit. The disease activity and disease-related outcome measures for these 239 patients  
169 are summarized in Table 2. At 6 months, the mean (SD) DAS28-CRP and SDAI were 3.04 (1.25) and  
170 11.37 (10.71) respectively (Supplementary Table 1). Based on EULAR response criterion, 110 (47.2%)  
171 patients had good response, 79 (33.9%) moderate and 44 (18.9%) no response. Regarding remission  
172 by different criteria, 97 (41.3%) patients achieved DAS28-CRP remission, 57 (24.3%) SDAI remission  
173 and 51 (21.5%) met the ACR/EULAR Boolean remission criteria reflecting increased stringency of  
174 definitions. All 57 patients in SDAI remission were in DAS28-CRP remission. There was excellent  
175 agreement between SDAI and ACR/EULAR Boolean remissions (Cohen's kappa of 0.9).

176 Other outcome measures are described in Supplementary Table 1.

### 177 *Predictors of clinical remission at 6 months*

178 Multivariate logistic regression models for SDAI and DAS28-CRP remissions are shown in Table 3. In  
179 both models, 6-month clinical remission was predicted by lower functional disability and disease  
180 activity at baseline. The odds ratios related to level of disease activity at baseline are 0.68 (95% CI:  
181 0.49-0.95) for a 10 unit change in SDAI or 0.70 (95% CI: 0.52-0.94) for a 1 unit change in DAS28-CRP,  
182 reflecting that patients with a baseline disease activity 10 (or 1) units higher have approximately a  
183 thirty percent reduction in odds of achieving 6-month remission, controlling for other variables.

## Characterization of disease course and remission in early seropositive rheumatoid arthritis

184 Higher baseline functional disability was associated with a reduced likelihood of achieving SDAI  
185 remission (OR=0.88, 95% CI: 0.82-0.96 for a 0.125 increase in HAQ) or DAS28-CRP remission  
186 (OR=0.91, 95% CI: 0.85-0.97 for a 0.125 increase in HAQ) at 6 months.

187 Although both models suggested alcohol consumption increased the odds of remission at 6 months  
188 compared to not consuming alcohol, they gave conflicting ordering of effect sizes across the alcohol  
189 consumption categories of 1-5 units and greater than 5 units per week. Moreover, the SDAI model  
190 included effects of baseline prescribed medication, with evidence that being prescribed dual  
191 combination of MTX and a second DMARD increased the likelihood of SDAI remission compared to  
192 receiving monotherapy (OR 3.13; 95%CI 1.15-8.50; p=0.026).

193 *Characterising disease activity over time*

194 Figure 1 (left hand side) shows the observed individual trajectories of SDAI and DAS28-CRP for the  
195 267 patients. From the figure there is evidence of substantive within- and between-patient variation  
196 in disease activity profiles and potential distinct trajectory subtypes.

197 Table 4 and Supplementary Table 2 show the results of fitting latent class mixed models to SDAI and  
198 DAS28-CRP respectively when accounting for the baseline prescribing of medication. Both models  
199 provide evidence for three distinct sub-populations or latent classes. Class 1 corresponds to an  
200 **Inadequate Responder (IR)** group that, *on average*, started with high baseline disease activity that  
201 early on showed improvement, in association with initial medication, and then plateaued with  
202 moderate to high levels of disease activity. Class 2 corresponds to a **Higher Baseline Activity**  
203 **Responder (HBAR)** group that, *on average*, started with high baseline disease activity but showed  
204 sustained improvement over time. Class 3 corresponds to a **Lower Baseline Activity Responder**  
205 **(LBAR)** group that, *on average*, started with moderate levels of disease activity and showed  
206 sustained improvement. (See right hand side plots of Figure 1 and Table 5.)

## Characterization of disease course and remission in early seropositive rheumatoid arthritis

207 The IR, HBAR and LBAR groups were estimated to comprise 6.5%, 22.4% and 71.1% of the patients  
208 based on the SDAI model and 21.7%, 21.3% and 57% of the patients based on the DAS28-CRP model.  
209 No overall statistically significant differences in mean age at entry, disease duration, SF-36 physical  
210 component score at entry, sex, smoking status, alcohol consumption and serology distributions were  
211 found across latent classes. However mean BMI ( $p=0.064$ ), mean baseline levels of functional  
212 disability ( $p=0.015$ ) and SF-36 mental component scores ( $p=0.05$ ) either were close to being or were  
213 statistically significantly different across the three classes/groups based on the SDAI model but not  
214 DAS28-CRP model. Table 5 shows that, based on the SDAI model, the LBAR group had on average  
215 significantly less functional disability than the other groups. A similar pattern was seen for mental  
216 health, with, on average, better mental health scores seen in the LBAR group (mean of 46) compared  
217 to both IR and HBAR (means of 40.2 and 43.1 respectively). Mean BMI was approximately  $3.5\text{kg}/\text{m}^2$   
218 higher in the IR group compared to the other SDAI groups. No evidence was found that prescribing  
219 behaviour of clinicians varied across the SDAI or DAS28-CRP defined groups. (See Supplementary  
220 Table 3.)

221 In the **IR** group, lower disease activity levels over time (measured by SDAI) were associated with  
222 being female, shorter symptom duration, consuming greater than 5 units of alcohol per week, less  
223 functional disability and better mental well-being at baseline. Being prescribed dual therapy of MTX  
224 and a second DMARD at baseline was associated with lower SDAI over time compared to either  
225 receiving monotherapy (excluding glucocorticoids) or therapies that included glucocorticoid usage  
226 (see Table 4).

227 For the **HBAR** group, lower levels of SDAI over time were associated with shorter symptom duration,  
228 increasing levels of alcohol consumption, and less functional disability. Moreover lower levels of  
229 disease activity were associated with being prescribed dual therapy of MTX and a second DMARD at  
230 baseline. In the **LBAR** group, being female, consuming alcohol and lower level of functional disability  
231 at baseline were associated with lower levels of SDAI.

## Characterization of disease course and remission in early seropositive rheumatoid arthritis

232 Based on the DAS28-CRP model (Supplementary Table 2), lower levels of functional disability, better  
233 mental well-being and dual therapy of MTX with a second DMARD at baseline were associated with  
234 lower DAS28-CRP over time in the IR group. Higher levels of functional disability and receiving  
235 monotherapy (excluding glucocorticoids) were associated with higher levels of disease activity in the  
236 HBAR group. Whilst being female, drinking alcohol, having lower levels of functional disability and  
237 better mental health were associated with lower DAS28-CRP over time in the LBAR group.

238 Table 5 summarises other patient outcome data (X-ray score, EQ-5D, HAQ, SF-36 MCS) by allocated  
239 latent trajectory class. Class assignment could be made for 263 of the 267 eligible patients with  
240 some baseline and outcome information. The average EQ-5D scores both at baseline and 6 months  
241 were significantly higher in the LBAR group than the other groups as defined by the SDAI model  
242 ( $p<0.0001$  and 0.049), whilst average level of functional disability remained significantly lower in this  
243 group at 6 months ( $p<0.0001$ ). There was no statistical evidence for a difference in average X-ray  
244 annualised progression rate across groups.

245

## 246 DISCUSSION

247 The TACERA cohort provides a unique opportunity to follow newly diagnosed and initially  
248 medication naïve patients in the UK, whose clinical outcomes are linked to extensive and detailed  
249 biological phenotyping (to be reported separately). We focused solely on seropositive RA patients  
250 whom have few non-severe comorbidities to reduce heterogeneity and to identify factors associated  
251 with outcomes in this subset.

252 We found clear evidence that remission at 6 months, whether defined using SDAI or DAS28-CRP, was  
253 associated with lower levels of disease activity and functional disability at baseline and with alcohol  
254 consumption at baseline. Aletaha et al.(27) have previously shown that disease activity early in the  
255 course of treatment predicts response to therapy after 1 year. However, other variables previously

## Characterization of disease course and remission in early seropositive rheumatoid arthritis

256 identified as associated with remission, such as age, gender, ethnicity and RA medications were not  
257 found to be statistically significant in our study. This may be due to the power of the current study  
258 (especially when restricted to the outcome defined at a single time point), to the use of a treat-to-  
259 target medication strategy, or to the fact that some variables may be less important in a pure  
260 seropositive disease cohort.

261 We also identified three trajectories of disease course and potential factors associated with them  
262 and also with disease activity levels within trajectories. We used the same trajectory labels (IR, HBAR  
263 and LBAR) in both SDAI and DAS28-CRP models, but the estimated proportion of patients who fell  
264 into the three groups varied according to the way disease activity was measured. Moreover the  
265 agreement between these two classifications was weak (Cohen's Kappa of 0.18); and significant  
266 overall associations of baseline functional disability and SF-36 mental component score and near  
267 significant association with BMI were found only with the SDAI trajectories; thus suggesting these  
268 disease activity indices are not interchangeable.

269 Interestingly, we found no evidence for differences in prescribing behaviour at baseline amongst the  
270 trajectory classes irrespective of how trajectory classifications were made. However we found clear  
271 evidence that, even as early as 6 months, disease outcomes (e.g. EQ-5D, HAQ) and their changes  
272 from baseline differed between trajectory groups, with the IR group generally having the least  
273 improvement and poorer health outcomes. No evidence for differing annualized X-ray progression  
274 rates were seen across groups. This may be expected given the short length of follow-up and early  
275 intensive management. The findings of very few if any significant associations between standard  
276 clinical measures and trajectory classes, and evidence of clear changes in outcomes as early as 6  
277 months would possibly suggest that these trajectories may instead be linked to distinct  
278 immunopathogenic subsets. Thus immunological biomarkers at baseline and early in follow-up  
279 (before 6 months) may be useful in identifying patients who beyond 6 months will have inadequate  
280 response to initial synthetic disease modifying treatment. We are currently investigating these

## Characterization of disease course and remission in early seropositive rheumatoid arthritis

281 trajectories from a biological viewpoint, utilising the extensive biological dataset collected in  
282 TACERA.

283 Heterogeneity in the effects of covariates on average SDAI level over time was seen across  
284 trajectories. Specifically, we found that effect sizes differed across trajectories with respect to  
285 functional disability, mental health, alcohol consumption and combination MTX with second DMARD  
286 compared to therapies with glucocorticoid usage. This provides evidence to support a stratified  
287 approach to management and treatment of patients falling into different trajectory groups.

288 Our results concerning the effect of alcohol consumption on both SDAI remission at 6 months and  
289 disease activity levels within SDAI trajectories suggest that consuming alcohol is associated with  
290 higher remission rates and lower disease activity over time. Similar inverse associations have been  
291 reported by other studies.(28–32) These findings may be due to alcohol intake being associated with  
292 lower levels of inflammatory markers and possibly because certain alcoholic drinks, for example red  
293 wine, may be anti-oxidant due to their flavonoid content, counteracting postprandial oxidative  
294 stress.(33,34)

295 The findings that mental health is a predictor of disease activity over time in the IR group and also  
296 possibly the LBAR group but not the HBAR group are worth highlighting. One-year results from the  
297 Scottish Early Rheumatoid Arthritis Inception (SERA) cohort have identified that predictors of  
298 functional disability at 1 year appear to be dominated by psychosocial rather than more traditional  
299 clinical measures, emphasising the potential benefit which may result from early access to non-  
300 pharmacological interventions targeting key psychosocial factors, such as mental health and work  
301 disability.(35) The possibility of adopting a non-pharmacological intervention strategy for those in  
302 the IR and LBAR (that make up approximately 78% of the RA patients) should be explored in more  
303 depth.

## Characterization of disease course and remission in early seropositive rheumatoid arthritis

304 Latent class mixed modelling approaches have only recently begun to be used to investigate whether  
305 distinct subpopulations exist within RA with respect to disease course.(5,36,37) Previous studies  
306 using DAS28 have identified similar trajectory groups. The larger study by Barnabe et al. was able to  
307 identify five trajectory groups instead of three. However combining their Groups 1 and 4 (i.e. both  
308 with initial high activity) into a single group would coincide with our HBAR group, whilst combining  
309 their Groups 2 and 3 (i.e. both with initial moderate activity) would correspond to our LBAR group.  
310 Our work applies also to SDAI and demonstrates similar trajectory groups within a purely  
311 seropositive population. Additionally, we controlled for factors that may impact on disease activity  
312 over time within these trajectory groups.

313

## 314 CONCLUSION

315 In conclusion, we found that, in early seropositive RA with few non-severe comorbidities, lower  
316 baseline levels of functional disability and disease activity, along with alcohol intake, are associated  
317 with 6-month clinical remission. We identified three subpopulations based on disease trajectories  
318 that not only differ in terms of disease course but also with regard to the effect of risk factors, such  
319 as mental well-being, on disease activity over time. Our data further highlight RA heterogeneity (i.e.  
320 trajectory classes) not explainable by clinical factors and indicate the possible use of biomarkers  
321 collected at baseline and early follow-up to help patient management and better targeting of  
322 existing and novel therapies.

323

## 324 Abbreviations

## 325 Availability of data and materials

326 Request for access to RA-MAP data and samples is

## Characterization of disease course and remission in early seropositive rheumatoid arthritis

### 327 **Funding**

328 This study was funded by the MRC/ABPI Inflammation and Immunology Initiative Grant (MRC  
329 reference numbers: G1001516 and G1001518). Dr Brian Tom is supported by the UK Medical  
330 Research Council (Unit Programme number MC\_UP\_1302/3 and MC\_UU\_00002/2).

### 331 **Authors' contribution and competing interests**

332 A list of contributing authors with disclosure of possible conflicts of interests can be found in "RA-  
333 MAP Contributing Authors\_ART\_2019.docx"

### 334 **Acknowledgements**

335 We acknowledge the support of TACERA Principal Investigators from all contributing NHS sites and  
336 the members of the TACERA Study Steering and Data Monitoring Committee. The Research was  
337 supported by the NIHR Newcastle Biomedical Research Centre. Members of the RA-MAP Consortium  
338 can be found in the document "RA-MAP Consortium Membership\_ART\_2019.docx".

### 339 **Ethics approval and consent to participate**

340 Ethical approval was authorised by the National Research Ethics Service London Central Committee  
341 (Reference number: 12/LO/0469). Informed, written consent was obtained.

### 342 **Consent for publication**

343 Not applicable

## Characterization of disease course and remission in early seropositive rheumatoid arthritis

### 344 REFERENCE

- 345 1. Scott DL, Wolfe F, Huizinga TW. *Rheum arthritis Lancet*. 2010;376:1094–108.
- 346 2. Cook MJ, Diffin J, Scire CA, Lunt M, MacGregor AJ, Symmons DPM, et al. Predictors and  
347 outcomes of sustained, intermittent or never achieving remission in patients with recent  
348 onset inflammatory polyarthritis: results from the Norfolk Arthritis Register. *Rheumatology*.  
349 2016;55(9):1601–9.
- 350 3. Ma MYH, Ibrahim F, Kingsley GH, Cope A, Scott DL. Variable impacts of different remission  
351 states on health-related quality of life in rheumatoid arthritis. *Clin Exp Rheumatol*.  
352 2018;36(2):203–9.
- 353 4. Wolfe F, Rasker JJ, Boers M, Wells GA, Michaud K. Minimal disease activity, remission, and  
354 the long-term outcomes of rheumatoid arthritis. *Arthritis Care Res (Hoboken)*.  
355 2007;57(6):935–42.
- 356 5. Siemons L, ten Klooster PM, Vinkemeijer HE, Glas CAW, van de Laar MAFJ. Distinct trajectories  
357 of disease activity over the first year in early rheumatoid arthritis patients following a treat-  
358 to-target strategy. *Arthritis Care Res (Hoboken)*. 2014;66(4):625–30.
- 359 6. Norton S, Fu B, Scott DL, Deighton C, Symmons DPM, Wailoo AJ, et al. Health Assessment  
360 Questionnaire disability progression in early rheumatoid arthritis: systematic review and  
361 analysis of two inception cohorts. In: *Seminars in arthritis and rheumatism*. 2014. p. 131–44.
- 362 7. Bukhari M, Thomson W, Naseem H, Bunn D, Silman A, Symmons D, et al. The performance of  
363 anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in  
364 inflammatory polyarthritis: results from the Norfolk Arthritis Register. *Arthritis Rheum Off J*  
365 *Am Coll Rheumatol*. 2007;56(9):2929–35.
- 366 8. Van Gaalen FA, Van Aken J, Huizinga TWJ, Schreuder GMT, Breedveld FC, Zanelli E, et al.  
367 Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides  
368 (CCPs) influences the severity of rheumatoid arthritis. *Arthritis Rheum Off J Am Coll*  
369 *Rheumatol*. 2004;50(7):2113–21.
- 370 9. Cope AP, Barnes MR, Belson A, Binks M, Brockbank S, Bonachela-Capdevila F, et al. The RA-  
371 MAP Consortium: a working model for academia-industry collaboration. *Nat Rev Rheumatol*.  
372 2018;14(1):53.
- 373 10. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham III CO, et al. 2010 rheumatoid  
374 arthritis classification criteria: an American College of Rheumatology/European League  
375 Against Rheumatism collaborative initiative. *Arthritis Rheum*. 2010;62(9):2569–81.
- 376 11. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American  
377 Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.  
378 *Arthritis Rheum Off J Am Coll Rheumatol*. 1988;31(3):315–24.
- 379 12. NICE. The management of rheumatoid arthritis in adults. (Clinical guideline 79.) [Internet].  
380 London; 2009. Available from: [www.nice.org.uk/CG79](http://www.nice.org.uk/CG79)
- 381 13. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease  
382 Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. *Clin Exp*  
383 *Rheumatol*. 2005;23(5):S100.
- 384 14. Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, et al. Rheumatoid arthritis

## Characterization of disease course and remission in early seropositive rheumatoid arthritis

- 385           disease activity measures: American College of Rheumatology recommendations for use in  
386           clinical practice. *Arthritis Care Res (Hoboken)*. 2012;64(5):640–7.
- 387       15. Anderson JK, Zimmerman L, Caplan L, Michaud K. Measures of rheumatoid arthritis disease  
388           activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease  
389           Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified  
390           Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score  
391           (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID),  
392           Rheumatoid Arthritis Disease Activity Index (RADAII) and Rheumatoid Arthritis Disease Activity  
393           Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity  
394           Score With ESR (PDAS1) and Patient-Based Disease Activity Score without ESR (PDAS2), and  
395           Mean Overall Index for Rheumatoid Arthritis (MOI-RA). *Arthritis Care Res (Hoboken)*.  
396           2011;63(S11):S14--S36.
- 397       16. Dougados M, Aletaha D, van Riel P. Disease activity measures for rheumatoid arthritis. *Clin Exp Rheumatol*. 2007;25(5):S22.
- 399       17. Felson DT, Smolen JS, Wells G, Zhang B, Van Tuyl LHD, Funovits J, et al. American College of  
400           Rheumatology/European League Against Rheumatism provisional definition of remission in  
401           rheumatoid arthritis for clinical trials. *Arthritis Rheum*. 2011;63(3):573–86.
- 402       18. Larsen A. A radiological method for grading the severity of rheumatoid arthritis. *Scand J Rheumatol*. 1975;4(4):225–33.
- 404       19. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related  
405           conditions by standard reference films. *Acta Radiol Diagnosis*. 1977;18(4):481–91.
- 406       20. Scott DL, Houssien DA, Laasonen L. Proposed modification to Larsen's scoring methods for  
407           hand and wrist radiographs. *Rheumatology*. 1995;34(1):56.
- 408       21. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis.  
409           *Arthritis Rheum*. 1980;23(2):137–45.
- 410       22. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in  
411           rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). *Br J Rheumatol*. 1997;36(5):551–9.
- 413       23. Linde L, Sørensen J, Østergaard M, Hørslev-Petersen K, Hetland ML. Health-related quality of  
414           life: validity, reliability, and responsiveness of SF-36, EQ-15D, EQ-5D, RAQoL, and HAQ in  
415           patients with rheumatoid arthritis. *J Rheumatol*. 2008;35(8):1528–37.
- 416       24. Ruta DA, Hurst NP, Kind P, Hunter M, Stubbings A. Measuring health status in British patients  
417           with rheumatoid arthritis: reliability, validity and responsiveness of the short form 36-item  
418           health survey (SF-36). *Br J Rheumatol*. 1998;37(4):425–36.
- 419       25. Team RC. R: A language and environment for statistical computing [Computer software].  
420           Vienna, Austria R Found Stat Comput. 2017;
- 421       26. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic  
422           comorbidity in longitudinal studies: development and validation. *J Chronic Dis*.  
423           1987;40(5):373–83.
- 424       27. Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of  
425           treatment predicts response to therapy after one year in rheumatoid arthritis patients.  
426           *Arthritis Rheum Off J Am Coll Rheumatol*. 2007;56(10):3226–35.

## Characterization of disease course and remission in early seropositive rheumatoid arthritis

- 427 28. Dunlop DD, Semanik P, Song J, Manheim LM, Shih V, Chang RW. Risk factors for functional  
428 decline in older adults with arthritis. *Arthritis Rheum.* 2005;52(4):1274–82.
- 429 29. Kim S-K, Park S-H, Shin I-H, Choe J-Y. Anti-cyclic citrullinated peptide antibody, smoking,  
430 alcohol consumption, and disease duration as risk factors for extraarticular manifestations in  
431 Korean patients with rheumatoid arthritis. *J Rheumatol.* 2008;35(6):995–1001.
- 432 30. Maxwell JR, Gowers IR, Moore DJ, Wilson AG. Alcohol consumption is inversely associated  
433 with risk and severity of rheumatoid arthritis. *Rheumatology.* 2010;49(11):2140–6.
- 434 31. Nissen MJ, Gabay C, Scherer A, Finckh A, in *Rheumatoid Arthritis SCQMP*. The effect of  
435 alcohol on radiographic progression in rheumatoid arthritis. *Arthritis Rheum.*  
436 2010;62(5):1265–72.
- 437 32. Papadopoulos NG, Alamanos Y, Voulgari P V, Epagelis EK, Tsifetaki N, Drosos AA. Does  
438 cigarette smoking influence disease expression, activity and severity in early rheumatoid  
439 arthritis patients? *Clin Exp Rheumatol.* 2005;23(6):861.
- 440 33. Covas MI, Gambert P, Fitó M, de la Torre R. Wine and oxidative stress: up-to-date evidence of  
441 the effects of moderate wine consumption on oxidative damage in humans. *Atherosclerosis.*  
442 2010;208(2):297–304.
- 443 34. Lu B, Solomon DH, Costenbader KH, Keenan BT, Chibnik LB, Karlson EW. Alcohol consumption  
444 and markers of inflammation in women with preclinical rheumatoid arthritis. *Arthritis*  
445 *Rheum.* 2010;62(12):3554–9.
- 446 35. Kronisch C, McLernon DJ, Dale J, Paterson C, Ralston SH, Reid DM, et al. Brief Report:  
447 Predicting Functional Disability: One-Year Results From the Scottish Early Rheumatoid  
448 Arthritis Inception Cohort. *Arthritis Rheumatol.* 2016;68(7):1596–602.
- 449 36. Barnabe C, Sun Y, Boire G, Hitchon CA, Haraoui B, Thorne JC, et al. Heterogeneous disease  
450 trajectories explain variable radiographic, function and quality of life outcomes in the  
451 Canadian Early Arthritis Cohort (CATCH). *PLoS One.* 2015;10(8):e0135327.
- 452 37. Wabe N, Sorich MJ, Wechalekar MD, Cleland LG, McWilliams L, Lee A, et al. Characterising  
453 deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years.  
454 *Arthritis Res Ther.* 2015;17(1):48.
- 455 38. Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP. The  
456 Charlson comorbidity index is adapted to predict costs of chronic disease in primary care  
457 patients. *J Clin Epidemiol.* 2008;61(12):1234–40.
- 458
- 459
- 460
- 461
- 462

Characterization of disease course and remission in early seropositive rheumatoid arthritis

463

464 **FIGURES LEGEND**

465

466 Figure1: Individual and mean disease activity profiles over 18 months stratified by predicted class

467 membership.

468

Characterization of disease course and remission in early seropositive rheumatoid arthritis

469

TABLES

470 Table 1: Baseline characteristics of patients in the TACERA study

Characteristics	Baseline (n=267)	
Age, years	53.1 (15.2)	
Female	192 (71.9%)	
White Ethnicity	194 (72.7%)	
BMI		
	Female	27.53 (6.47)
	Male	27.43 (4.97)
	Overall	27.50 (6.08)
BMI Status		
	Underweight: <18.5	9 (3.4%)
	Healthy weight: [18.5,25)	85 (31.8%)
	Overweight: [25,30)	95 (35.6%)
	Obese: ≥30	78 (29.2%)
Smoking		
	Never smoked	95 (35.6%)
	Previous smoker	104 (39.0%)
	Current smoker	68 (25.4%)
Alcohol consumption		
	None	86 (32.3%)
	1-5 units per week	115 (43.2%)
	6-10 units per week	25 (9.4%)
	11-15 units per week	11 (4.1%)
	16-20 units per week	15 (5.7%)

## Characterization of disease course and remission in early seropositive rheumatoid arthritis

More than 20 units per week	14 (5.3%)
Alcohol frequency	
Not Drinking	86 (32.2%)
1-2 days a year	28 (10.5%)
1-2 days a month	48 (18.0%)
1-2 days a week	58 (21.7%)
3-4 days a week	28 (10.5%)
5 days or more a week	19 (7.1%)
RF positive	247 (92.5%)
ACPA positive	230 (86.1%)
Disease Duration (years)	0.43 (0.23)
X-ray Larsen's Score (hands and feet)	6.70 (8.76)
Charlson's Comorbidity Index (original)	0.44 (0.84)
Charlson's Comorbidity Index (2008)(38)	0.81 (1.10)
SDAI	28.80 (14.29)
DAS28-CRP	4.85 (1.22)
Prescribed Medication	
Methotrexate (MTX)	202 (75.7%)
Hydroxychloroquine	141 (52.8%)
Leflunomide	0 (0.0%)
Sulfasalazine	18 (6.7%)
Oral glucocorticoids	17 (6.4%)
Parenteral glucocorticoids	126 (47.2%)
No RA medication	2 (0.7%)
Medication combinations prescribed	
No RA medication	2 (0.7%)
MTX only	51 (19.1%)

## Characterization of disease course and remission in early seropositive rheumatoid arthritis

Other DMARDs only	20 (7.5%)
Oral glucocorticoids only	2 (0.7%)
PARENTERAL glucocorticoids only	15 (5.6%)
MTX & other DMARDs	53 (19.9%)
MTX & oral glucocorticoids	6 (2.2%)
MTX & parenteral glucocorticoids	33 (12.4%)
Other DMARDs & oral glucocorticoids	2 (0.7%)
Other DMARDs & parenteral glucocorticoids	23 (8.6%)
oral & parenteral glucocorticoids	1 (0.4%)
MTX, other DMARDs & oral glucocorticoids	5 (1.9%)
MTX, other DMARDs & parenteral glucocorticoids	53 (19.9%)
MTX, oral & parenteral glucocorticoids	1 (0.4%)
Medication pyramid	
No RA medication	2 (0.7%)
MTX only	51 (19.1%)
Other DMARDs without glucocorticoids	73 (27.4%)
Glucocorticoids with/without other RA medication	141 (52.8%)

471    Values are number (percentage) or mean (standard deviation)

472

Characterization of disease course and remission in early seropositive rheumatoid arthritis

473 Table 2: Disease activity response and remission at 6 months

<b>Characteristics</b>	<b>6-month</b>	<b>6-month change</b>
	(n=239)	from baseline
DAS28-CRP Remission (DAS28-CRP < 2.6)*	97 (41.3%)	
DAS28-ESR Remission (DAS28-ESR < 2.6)*	92 (39.0%)	
SDAI Remission (SDAI ≤ 3.3)*	57 (24.3%)	
ACR/EULAR Boolean Remission*	51 (21.5%)	
EULAR Response*		
Good response	110 (47.2%)	
Moderate response	79 (33.9%)	
No response	44 (18.9%)	

474 \*Based on those with outcome not missing

Characterization of disease course and remission in early seropositive rheumatoid arthritis

475 Table 3: Multivariate Logistic Regression Models for SDAI and DAS28-CRP remission at 6 months

Predictors	Log (Odds	Standard	p-value
	Ratio)	Error	
<b>SDAI remission at 6 months</b>			
Intercept	0.128	0.547	0.814
SDAI at Baseline	-0.038	0.017	0.021
HAQ at Baseline	-0.979	0.313	0.002
Alcohol consumption			
1-5 units per week v None	1.278	0.461	0.006
>5 units per week v None	0.833	0.500	0.096
Prescribed medication at baseline*			
MTX and other DMARDs without glucocorticoids v therapies with glucocorticoids	0.416	0.431	0.334
monotherapy, not glucocorticoids v therapies with glucocorticoids	-0.724	0.433	0.094
<b>DAS28-CRP remission at 6 months</b>			
Intercept	1.519	0.677	0.025
DAS28-CRP at Baseline	-0.362	0.153	0.018
HAQ at Baseline	-0.758	0.268	0.005
Alcohol consumption			
1-5 units per week v None	0.865	0.360	0.016
>5 units per week v None	1.367	0.414	0.001

476 \* The contrast of MTX and other DMARDs without glucocorticoids versus monotherapy gave a Log

477 (Odds Ratio) estimate of 1.140 with standard error of 0.510 and a p-value of 0.026

478

## Characterization of disease course and remission in early seropositive rheumatoid arthritis

479

480 Table 4: Latent Class Mixed Model for SDAI while Controlling for Baseline Medication: 3 Classes

<b>Multinomial Class Membership Model</b>		<b>Estimate</b>	<b>Standard</b>	<b>p-value</b>
		<b>Error</b>		
<b>Class 1 (IR) v Class 3 (LBAR)</b>				
	Intercept	-2.118	0.289	0.000
<b>Class 2 (HBAR) v Class 3 (LBAR)</b>				
	Intercept	-0.721	0.225	0.001
<b>Linear Mixed Model</b>		<b>Estimate</b>	<b>Standard</b>	<b>p-value</b>
		<b>Error</b>		
Intercept				
	Class 1	27.360	4.769	0.000
	Class 2	15.972	2.593	0.000
	Class 3	21.062	1.746	0.000
Disease duration, months				
	Class 1	1.275	0.526	0.015
	Class 2	0.675	0.223	0.002
	Class 3	0.136	0.142	0.339
Sex				
	Male v Female Class 1	14.495	3.383	0.000
	Male v Female Class 2	2.039	1.800	0.257
	Male v Female Class 3	1.747	0.873	0.045
Alcohol consumption, units per week				
	1-5 units per week vs None Class 1	-2.007	3.946	0.611
	1-5 units per week vs None Class 2	-5.420	1.699	0.001
	1-5 units per week vs None Class 3	-1.430	0.814	0.079

Characterization of disease course and remission in early seropositive rheumatoid arthritis

>5 units per week vs None Class 1	-11.588	5.035	0.021
>5 units per week vs None Class 2	-4.772	1.738	0.006
>5 units per week vs None Class 3	-2.641	1.070	0.014
HAQ score at baseline			
Class 1	5.639	1.417	0.000
Class 2	9.897	0.948	0.000
Class 3	4.070	0.557	0.000
Centred SF-36 Mental component score at baseline			
Class 1	-0.309	0.114	0.007
Class 2	0.090	0.060	0.133
Class 3	-0.059	0.035	0.095
Follow-up time (in months) within 5 months			
Class 1	-2.456	0.819	0.003
Class 2	-2.346	0.444	0.000
Class 3	-4.005	0.260	0.000
Follow-up time (in month) after 5 months			
Class 1	0.837	0.265	0.002
Class 2	0.112	0.145	0.440
Class 3	0.047	0.089	0.595
Prescribed other DMARDs and MTX, not glucocorticoids v therapies with glucocorticoids at baseline			
Class 1	-18.742	2.775	0.000
Class 2	-7.456	1.775	0.000
Class 3	-0.838	1.331	0.529
Prescribed monotherapy, not glucocorticoids v therapies with glucocorticoids at baseline			
Class 1	5.398	3.394	0.112

Characterization of disease course and remission in early seropositive rheumatoid arthritis

Class 2	-1.905	1.475	0.197
Class 3	0.662	0.890	0.457

---

Variance Components

Variance of Random Intercept	74.947
Variance of Random Slope within 5 months	3.256
Variance of Random Slope after 5 months	0.050
Error Standard Deviation	7.600

---

481      IR – Inadequate Responder Group; HBAR – Higher Baseline Activity Responder Group;

482      LBAR – Lower Baseline Activity Responder Group

483

Characterization of disease course and remission in early seropositive rheumatoid arthritis

484

485 Table 5: Disease outcomes by allocated SDAI (1<sup>st</sup> row of cell) and DAS28-CRP (2<sup>nd</sup> row of cell)

486 classes, controlling for baseline medication

	Class 1 (IR)	Class 2 (HBAR)	Class3 (LBAR)	p-value
Baseline SDAI (SD)	44.65 (17.50)	32.08 (11.99)	26.44 (13.66)	<0.0001
	33.63 (16.28)	38.83 (12.95)	23.23 (11.05)	<0.0001
SDAI at 6 months (SD)*	32.84 (14.10)	18.74 (8.97)	7.36 (6.82)	<0.0001
	21.71 (13.14)	6.85 (6.38)	9.14 (8.29)	<0.0001
SDAI 6-month change from baseline	-9.11 (18.70)	-12.83 (12.74)	-19.37 (14.12)	0.002
	-11.00 (13.92)	-33.28 (13.94)	-13.76 (10.04)	<0.0001
DAS28-CRP (baseline)	5.89 (1.29)	5.19 (1.03)	4.65 (1.22)	<0.0001
	5.22 (1.24)	5.73 (0.89)	4.38 (1.11)	<0.0001
DAS28-CRP (6 months)	5.12 (1.23)	3.99 (1.02)	2.58 (0.93)	<0.0001
	4.22 (1.27)	2.50 (0.81)	2.79 (1.08)	<0.0001
DAS28-CRP 6-month change from baseline	-0.55 (1.37)	-1.19 (1.15)	-2.11 (1.29)	<0.0001
	-0.92 (1.15)	-3.32 (1.08)	-1.59 (1.04)	<0.0001
X-ray Score (baseline)	5.65 (5.88)	6.12 (10.83)	6.80 (8.05)	0.786
	6.11 (9.52)	7.23 (8.51)	6.50 (8.31)	0.779
X-ray annualized progression rate	1.00 (2.30)	1.08 (2.86)	0.89 (2.61)	0.898
	1.39 (3.64)	0.79 (2.04)	0.80 (2.32)	0.372
EQ5D Score (baseline)	0.33 (0.38)	0.43 (0.31)	0.52 (0.32)	0.030
	0.43 (0.33)	0.45 (0.34)	0.52 (0.32)	0.094
EQ5D Score (6 months)*	0.50 (0.34)	0.59 (0.27)	0.77 (0.21)	<0.0001
	0.63 (0.27)	0.79 (0.18)	0.72 (0.25)	0.003
EQ5D 6-month change from baseline	0.11 (0.25)	0.15 (0.33)	0.25 (0.31)	0.049
	0.18 (0.27)	0.36 (0.35)	0.18 (0.29)	0.002
HAQ (baseline)	1.41 (0.80)	1.44 (0.72)	1.13 (0.76)	0.015
	1.21 (0.72)	1.29 (0.81)	1.20 (0.76)	0.748

## Characterization of disease course and remission in early seropositive rheumatoid arthritis

HAQ (6 months)*	1.10 (0.94)	1.15 (0.80)	0.50 (0.58)	<0.0001
	0.93 (0.83)	0.50 (0.61)	0.65 (0.68)	0.008
HAQ 6-month change from baseline	-0.19 (0.77) -0.23 (0.60)	-0.25 (0.63) -0.82 (0.81)	-0.63 (0.60) -0.52 (0.52)	0.0001 <0.0001
SF-36 MCS (baseline)	40.2 (11.9)	43.1 (11.7)	46 (11.3)	0.05
	44.4 (11.4)	46.5 (12.2)	44.6 (11.3)	0.632
SF-36 MCS (6 months)*	41.2 (10.3)	46.2 (13.3)	50.9 (10.5)	0.0006
	46.4 (11.7)	55.1 (7.4)	48.3 (12.0)	0.0002
SF-36 MCS 6-month change from baseline	0.15 (11.67) 1.54 (10.68)	3.05 (12.36) 7.61 (10.25)	4.65 (9.74) 3.64 (10.23)	0.217 0.012

487 Mean (SD) are reported with p-values based on ANOVA test; IR – Inadequate Responder Group

488 HBAR – Higher Baseline Activity Responder Group; LBAR – Lower Baseline Activity Responder

489 Group

490 \* Number of patients at 6 months differs from the number at baseline within a class


491

Characterization of disease course and remission in early seropositive rheumatoid arthritis

492

FIGURES

493



494

495 Figure1: Individual and mean disease activity profiles over 18 months stratified by predicted class  
496 membership\*.

497 \*Based on SDAI, Class1 (Red; Inadequate Response [IR]): 17 (6.5%), Class 2 (Green; Higher  
498 Baseline Activity Responder [HBAR]): 59 (22.4%), Class 3 (Blue; Lower Baseline Activity Responder  
499 [LBAR]): 187 (71.1%). Based on DAS28-CRP, Class1 (Red; IR): 57 (21.7%), Class 2 (Green; HBAR):  
500 56 (21.3%), Class 3 (Blue; LBAR): 150 (57.0%).

501